John T Schiller

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Virus infection and human cancer: an overview
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Recent Results Cancer Res 193:1-10. 2014
  2. doi request reprint A review of clinical trials of human papillomavirus prophylactic vaccines
    John T Schiller
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Vaccine 30:F123-38. 2012
  3. doi request reprint Vaccines to prevent infections by oncoviruses
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Annu Rev Microbiol 64:23-41. 2010
  4. pmc Current understanding of the mechanism of HPV infection
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Gynecol Oncol 118:S12-7. 2010
  5. doi request reprint Cutaneous squamous cell carcinoma: a smoking gun but still no suspects
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Invest Dermatol 131:1595-6. 2011
  6. pmc In vivo mechanisms of vaccine-induced protection against HPV infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 8:260-70. 2010
  7. pmc Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization
    Alessandra Handisurya
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:13214-25. 2013
  8. pmc Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species
    Alessandra Handisurya
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 433:385-94. 2012
  9. pmc Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
  10. pmc Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 103:737-43. 2011

Collaborators

Detail Information

Publications56

  1. doi request reprint Virus infection and human cancer: an overview
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Recent Results Cancer Res 193:1-10. 2014
    ..Successful efforts to identify additional oncogenic viruses in human cancer may lead to further insight into etiology and pathogenesis as well as to new approaches for therapeutic and prophylactic intervention...
  2. doi request reprint A review of clinical trials of human papillomavirus prophylactic vaccines
    John T Schiller
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Vaccine 30:F123-38. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  3. doi request reprint Vaccines to prevent infections by oncoviruses
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Annu Rev Microbiol 64:23-41. 2010
    ..Efforts to develop KSHV vaccines have been more limited...
  4. pmc Current understanding of the mechanism of HPV infection
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Gynecol Oncol 118:S12-7. 2010
    ....
  5. doi request reprint Cutaneous squamous cell carcinoma: a smoking gun but still no suspects
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Invest Dermatol 131:1595-6. 2011
    ..Their findings show that it is very unlikely that any currently known virus is commonly responsible for the maintenance of this cancer...
  6. pmc In vivo mechanisms of vaccine-induced protection against HPV infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 8:260-70. 2010
    ..Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo...
  7. pmc Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization
    Alessandra Handisurya
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:13214-25. 2013
    ....
  8. pmc Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species
    Alessandra Handisurya
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 433:385-94. 2012
    ....
  9. pmc Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
    ..We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18...
  10. pmc Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 103:737-43. 2011
    ..Therefore, we determined whether a cytology specimen collection procedure (Pap smear), which disrupts the epithelium by design, renders the cervix more susceptible to HPV infection in a primate model...
  11. pmc Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 82:4638-46. 2008
    ..These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines...
  12. pmc Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
    Aimee R Kreimer
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 12:862-70. 2011
    ..Human papillomavirus (HPV) 16 and 18 infections cause most cases of anal cancer. We assessed efficacy of an AS04-adjuvanted HPV 16 and HPV 18 vaccine against anal infection with HPV 16, HPV 18, or both (HPV 16/18)...
  13. pmc Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease
    Anil K Chaturvedi
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072 Rockville, MD 20852, USA
    J Infect Dis 203:910-20. 2011
    ..We investigated coinfection patterns for 25 human papillomavirus (HPV) types and assessed the risk conferred by multiple HPV types toward cervical disease...
  14. ncbi request reprint Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  15. pmc The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding
    Rhonda C Kines
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:20458-63. 2009
    ....
  16. pmc Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine
    Aimee R Kreimer
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7084, Rockville, MD 20852, USA
    J Natl Cancer Inst 103:1444-51. 2011
    ..Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest...
  17. pmc Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 81:8784-92. 2007
    ..We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes...
  18. pmc Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses
    Nicolas Cuburu
    Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 122:4606-20. 2012
    ..Thus, HPV vectors are attractive gene-delivery platforms for inducing durable intraepithelial cervicovaginal CD8+ T cell responses by promoting local proliferation and retention of primed antigen-specific CD8+ T cells...
  19. pmc Maturation of papillomavirus capsids
    Christopher B Buck
    Laboratory of Cellular Oncology, Building 37, Room 4106, 9000 Rockville Pike, Bethesda, MD 20892 4263, USA
    J Virol 79:2839-46. 2005
    ..Despite their obvious morphological differences, mature and immature capsids are similarly neutralizable by various L1- and L2-specific antibodies...
  20. pmc Human alpha-defensins block papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892 4263, USA
    Proc Natl Acad Sci U S A 103:1516-21. 2006
    ....
  21. ncbi request reprint Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 337:365-72. 2005
    ..BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes...
  22. ncbi request reprint Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, 9609 Medical Center Drive, Rm 6 E224, MSC 9767, Bethesda, MD 20892
    Cancer Prev Res (Phila) 6:1242-50. 2013
    ..Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection...
  23. pmc Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
    J Natl Cancer Inst 102:1653-62. 2010
    ..Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown...
  24. ncbi request reprint Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
    Eur J Immunol 35:1548-56. 2005
    ..Finally, CpG-activated pDC, but not pDC exposed to HPV16 VLP, activated lymphocytes to secrete IL-10 and low levels of IFN-gamma. Together these findings suggest a possible immunogenic effect of pDC in the setting of VLP vaccination...
  25. pmc Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus
    Katherine M Johnson
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:2067-74. 2009
    ..We speculate that cutaneous HPVs, such as HPV5, and genital mucosal HPVs, such as HPV16 and -31, may have evolved to recognize different forms of HSPGs to enable them to preferentially infect keratinocytes at different anatomical sites...
  26. pmc Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:3862-70. 2013
    ..Additionally, Rab9a and Rab7b were determined to be mediators of this transit, as expression of dominant negative versions of these proteins, but not Rab7a, significantly inhibited HPV16 pseudovirus infection...
  27. pmc A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 19:1075-82. 2012
    ..This "L2-based" in vitro neutralization assay should prove useful in critically evaluating the immunogenicity of L2 vaccine candidates in preclinical studies and future clinical trials...
  28. pmc Carrageenan is a potent inhibitor of papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA
    PLoS Pathog 2:e69. 2006
    ..Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs...
  29. pmc Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA
    Shari N Gordon
    Animal Models and Retroviral Vaccines Section, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 188:714-23. 2012
    ....
  30. pmc Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection
    Rebecca M Richards
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:1522-7. 2006
    ..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition...
  31. pmc In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system
    Makoto Mitsunaga
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:767-73. 2011
    ..This method offers the ability to monitor experimental virus infections before and after intervention, thereby accelerating the development of appropriate prevention and therapy...
  32. ncbi request reprint Generation of HPV pseudovirions using transfection and their use in neutralization assays
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 119:445-62. 2005
    ..Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA)...
  33. pmc Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:14252-7. 2004
    ..The results identify a role for PML in the enhancement of viral infectivity in the early part of the life cycle. We propose a model in which L2 chaperones the viral genome to ND10 to efficiently initiate viral transcription...
  34. ncbi request reprint Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4263, USA
    Nat Med 13:857-61. 2007
    ..In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide...
  35. pmc Arrangement of L2 within the papillomavirus capsid
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
    J Virol 82:5190-7. 2008
    ..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle...
  36. doi request reprint Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica
    Sarah Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS, Room 7079, Rockville, MD 20852, USA
    Sex Transm Dis 37:706-14. 2010
    ..We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25...
  37. ncbi request reprint New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer
    May Wong
    Biological Carcinogenesis Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Natl Cancer Inst 94:1832-6. 2002
  38. pmc Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
    Sholom Wacholder
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rockville, MD 20852, USA
    BMJ 340:c712. 2010
    ..To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage...
  39. doi request reprint Human papillomavirus infection and the primary and secondary prevention of cervical cancer
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 113:1980-93. 2008
    ..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer...
  40. pmc Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Virol 82:12565-8. 2008
    ..We conclude that the primary function of HSPG binding is to enable cell surface furin cleavage of L2 and that binding to a distinct cell surface receptor(s) is a subsequent step of papillomavirus infection...
  41. pmc Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus
    Bryce Chackerian
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:4037-47. 2004
    ....
  42. pmc Prophylactic human papillomavirus vaccines
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 116:1167-73. 2006
    ..Unresolved issues include the most critical groups to vaccinate and when the vaccine's cost may be low enough for widespread implementation in the developing world, where 80% of cervical cancer occurs...
  43. ncbi request reprint Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4040, USA
    Clin Immunol 106:231-7. 2003
    ..Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant...
  44. pmc The role of furin in papillomavirus infection
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Future Microbiol 4:1255-62. 2009
    ..This work also has implications for further advances in papillomavirus vaccine development...
  45. ncbi request reprint Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice
    Jiahua Qian
    Vaccine Branch, NCI, National Naval Medical Center, Bldg 8, Bethesda, MD 20892, USA
    Int J Cancer 118:3022-9. 2006
    ....
  46. pmc An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA
    Vaccine 26:K53-61. 2008
    ..The results of these studies have led to the approval of Gardasil and Cervarix by national regulatory agencies in a number of countries...
  47. pmc Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
    J Virol 78:751-7. 2004
    ..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
  48. ncbi request reprint Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China
    Farin Kamangar
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 119:579-84. 2006
    ..4). For HPV 73, these figures were 1.3 (0.6-2.5), 1.2 (0.6-2.3) and 0.9 (0.4-2.1). The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China...
  49. pmc Reducing HPV-associated cancer globally
    Douglas R Lowy
    Laboratory of Cellular Oncology, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 5:18-23. 2012
    ..Second-generation HPV vaccines (active against a broader array of cervical cancer-related HPV types) could prevent an even higher proportion of cervical precancer and cancer and might permit further reductions in screening intensity...
  50. ncbi request reprint Delivering on the promise: HPV vaccines and cervical cancer
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Rev Microbiol 2:343-7. 2004
  51. ncbi request reprint Papillomaviruses infect cells via a clathrin-dependent pathway
    Patricia M Day
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 36, Room 1D 32, Bethesda, MD 20892, USA
    Virology 307:1-11. 2003
    ..Surprisingly, the kinetics of internalization were unusually slow for this mechanism, with the t(1/2) of entry of BPV-1 being approximately 4 h versus 5-15 min for a typical ligand...
  52. doi request reprint Understanding and learning from the success of prophylactic human papillomavirus vaccines
    John T Schiller
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 10:681-92. 2012
    ....
  53. ncbi request reprint Prospects for cervical cancer prevention by human papillomavirus vaccination
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:10229-32. 2006
    ..These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women...
  54. ncbi request reprint Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
    Allan Hildesheim
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    JAMA 298:743-53. 2007
    ..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy...
  55. ncbi request reprint Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
    Bryce Chackerian
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:6120-6. 2002
    ....
  56. ncbi request reprint Chapter 17: Second generation HPV vaccines to prevent cervical cancer
    John T Schiller
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Vaccine 24:S3/147-53. 2006
    ..Three questions need to be addressed: (1) Is there sufficient need for a second generation vaccine? (2) Are there sufficiently attractive candidates for clinical trials? (3) Is there a realistic development/commercialization path?..